Return to homepagePandemic Pact

Development of an animal model and accelerated development of a DNA vaccine candidate (SCARD SARS-CoV-2 project)

  • Funded by Institut Pasteur International Network (IPIN)
  • Total publications:0 publications

Grant number: SCARD SARS-CoV-2

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Institut Pasteur International Network (IPIN)

  • Principal Investigator

    N/A

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Aims:To develop a mouse model of SARS-CoV-2 infection.This will not only enable us to evaluate the efficacy of the vaccine; it will also facilitate in vivo research on SARS-CoV-2. To evaluate the immunogenicity (ability to induce a specific immune reaction) and efficacy (protection capability) of DNA-based vaccine candidates.DNA vaccination is a technique for protecting against disease by injecting DNA encoding a specific antigen. The injected DNA triggers a protective immunological response, for example the production of antibodies against the antigen. DNA vaccines offer potential advantages compared with conventional vaccines, including the ability to induce a wider range of immune response types. Two antigen candidates have already been designed, based on the S (spike) protein of the virus, responsible for the "crown" ("corona" in Latin) observed at the surface of coronaviruses, after which they were named.